VivaVision Biotech Launches Phase III Clinical Trial of VVN461 Ophthalmic Solution for Non-Infectious Anterior Uveitis

Data from the Drug Clinical Trial Registration and Information Disclosure Platform shows that VIVAVISION has initiated a Phase III clinical trial to evaluate the efficacy and safety of 1.0% VVN461 eye drops in patients with non-infectious anterior uveitis. This is a randomized, single-blind, positive-controlled, multicenter study. The clinical trial registration number is CTR20253764, with the initial information disclosure date on September 17, 2025.

The drug formulation is an eye drop, with a specification of 1.0% (10 mg/mL). The usage and dosage are as follows: apply topically to the eye, one drop per study eye, six times daily for 7 days; four times daily for 7 days; twice daily for 7 days; once daily for 7 days, with continuous administration for 4 weeks. The primary objective of this trial is to evaluate the efficacy of the 1.0% VVN461 eye drops in patients with non-infectious anterior uveitis.

VVN461 Eye Drops is a chemical drug indicated for non-infectious anterior uveitis. Non-infectious anterior uveitis is a non-infectious inflammation affecting the anterior segment of the uvea, with symptoms including eye pain, photophobia, tearing, etc., and diagnosis relies on ophthalmic examinations such as slit-lamp tests.

The primary endpoint of this trial was the change in the anterior chamber cell score of the study eye compared to baseline at the Day 14 visit; secondary endpoints included the proportion of participants with an anterior chamber cell score of 0 for the study eye and the proportion of participants who experienced treatment failure (requiring rescue therapy) during the study treatment period.

Currently, the experiment status is ongoing (not yet recruiting).

Risk Warning: The market carries risks, and investments should be made with caution. This article is automatically published by an AI large model based on a third-party database. Any information appearing in this article (including but not limited to individual stocks, comments, forecasts, charts, indicators, theories, or any form of expression, etc.) is for reference only and does not constitute personal investment advice. Due to issues such as the quality of the third-party database, we are unable to verify or confirm the authenticity and completeness of the data. Therefore, the content of this article may contain inaccuracies, incompleteness, or misleading information. Please refer to official company announcements for details. If you have any questions, please contact biz@staff.sina.com.cn.

Editor: Xiaolang Express